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Abstract
Background: There have been concerns about the possible prothrombotic effects of nilotinib, especially in patients having
cardiovascular risk factors. The potential mechanism behind the increased risk of thromboembolic events is still not clear.
Objectives: In this study, we aimed to evaluate possible harmful effects of nilotinib on endothelial cells. To this aim, we examined
proliferative capacity and secretory functions of healthy human carotid artery endothelial cells (HCtAECs) in response to
nilotinib. Methods: 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation method was used to
determine antiproliferative effects of nilotinib on HCtAECs. The HCtAECs were incubated with 5, 10, and 100 nmol/L doses
of nilotinib for 72 hours. Then, in order to assess the endothelial function, levels of nitric oxide (NO), von Willebrand factor
(vWF), tissue plasminogen activator, plasminogen activator inhibitor 1 (PAI-1), and endothelin 1 (ET-1) were evaluated using
enzyme-linked immunosorbent assay from tissue culture supernatants. Results: There were slight but statistically significant
decreases in cell proliferation in response to nilotinib. Nilotinib increased the secretion of t-PA, PAI-1, and vWF in a dose-
dependent manner when compared with the untreated control group. The ET-1 secretion was lower in 5 nmol/L and higher
in 10 and 100 nmol/L nilotinib-treated cells as compared to untreated cells. Regarding NO secretion, lower levels were observed
in 5 and 10 nmol/L, and higher levels were detected in 100 nmol/L nilotinib-treated cells as compared to untreated control group
cells.Conclusion: Considering the results obtained in our study, nilotinib does not affect the functions of endothelial cells either
in a prothrombotic or an antithrombotic fashion, despite a dose-dependent decline in cell viability.
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Introduction
Chronic myeloid leukemia (CML) is a clonal disease of pluri-
potent stem cell and is associated with fusion of the 2 genes:
BCR (on chromosome 22) and ABL (on chromosome 9) result-
ing in the BCRABL1 fusion protein. Deregulated tyrosine
kinase activity of this abnormal fusion protein is implicated
in the pathogenesis of CML.1,2
Nilotinib (Tasigna [nilotinib], formerly known as AMN107;
Novartis) is a novel oral aminopyrimidine derivative that has
been rationally designed to be more selective against the
Bcr-Abl tyrosine kinase than imatinib. Nilotinib competitively
inhibits adenosine triphosphate binding site of BCRABL1 with
higher affinity and specificity than imatinib. The superior
effects of nilotinib may result from its strong effects on
BCR/ABL (including BCR/ABL-mutants) and its effects on
additional drug targets. However, such additional targets are
also expressed in nonhematopoietic cells and may thus be
responsible for nonhematologic adverse events.
The most common nonhematologic side effects reported are
skin rashes, headache, diarrhea, elevations of pancreatic
enzymes, serum bilirubin, and fasting plasma glucose. Gener-
ally, these side effects are self-limited or easily
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manageable.3-5 Despite these nonlife-threatening side effects,
some serious side effects such as severe and treatment resistant
peripheral arterial occlusive disease and some other vascular
occlusive conditions are being published in either patients who
were just on nilotinib therapy or the ones who has switched
from imatinib to nilotinib.6-8
Up to now, it is well established that these serious side
effects are commonly seen in patients who are just harboring
well-known vascular disease risk factors like smoking, arterial
hypertension, diabetes mellitus, obesity, or advanced age. But
still it is unclear that which of the patients on nilotinib therapy
are candidates for vascular unwanted complications.6,7
Some possible explanations are proposed considering the
pathogenetic mechanisms of vascular side effects like metabolic
side effects of the drug, direct cytotoxic effects of the drug on vas-
cular cells, or the effect of the drug on coagulant and fibrinolytic
system.But still it is unclear thatwhich of these proposedmechan-
isms is the key factor inducing the unwanted vascular events.3
Considering the venous thromboembolic events, the main
responsible pathogenetic mechanisms are stasis and soluble
coagulant factors. Unlikely in arterial occlusive diseases, the
main pathogenetic mechanisms are endothelial injury and dys-
function. In this manner, we hypothesized that the cytotoxic
effects and concurrent endothelial dysfunction caused by nilo-
tinib, which are mainly associated with the alteration of path-
ways related to tyrosine kinase inhibition, are responsible
from the unwanted arterial occlusive side effects. In order to
establish the effect of the drug on endothelial cell viability and
function, we designed a cell culture study with healthy carotid
artery endothelial cells. We evaluated the cell viability with
increasing doses of nilotinib and endothelial function with
measuring nitric oxide (NO), plasminogen activator inhibitor
1 (PAI-1), endothelin 1 (ET-1), tissue plasminogen activator,
and von Willebrand factor (vWF).
Materials and Methods
Chemicals
The stock solution of nilotinib was dissolved in dimethyl-
sulfoxide (DMSO) at a concentration of 10 mmol/L, stored at
20C, and diluted in cell culture medium. The final concen-
tration of DMSO did not exceed more than 0.1% in culture.
Artery endothelial cell growth medium was obtained from Cell
Applications Inc (San Diego, California. ABD).
Cell Line and Culture Conditions
Human carotid artery endothelial cells (HCtAECs) were
obtained from Cell Applications Inc (ABD) and grown in
T-75 flask containing 15 mL of artery endothelial cell growth
medium under conditions as recommended by the manufac-
turer. Briefly, the cells were incubated in a 5% CO2 atmosphere
at 37C and passaged when reaching 80% confluency. In order
to avoid any changes in cell physiology, the cells were only
used within 3 to 5 passages. The HCtAECs were previously
used to demonstrate the endothelial responses to hemodynamic
stress and inflammation.9-11
Measurement of Cytotoxic Effects of Nilotinib on
HCtAECs by 3-(4,5-Dimethylthiazolyl-2)-2,5-
diphenyltetrazolium Bromide Cell Proliferation Assay and
Determination of Nilotinib Effect on HCtAEC Confluency
Because of the cell culture—in vitro design of the study, the in
vivoeffective plasmaconcentrations ofnilotinibwas ignored, and
cytotoxic effects of nilotinib on HCtAECs were determined
by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
(MTT) cell proliferation assay. The basic principle of this assay is
based on the reduction of the yellow tetrazoliumMTT inmetabo-
lically active cells by the actionofdehydrogenase enzymespartly.
The resulting intracellular purple formazan can be solubilized and
quantified by spectrophotometric techniques. In short, 5  103
cells/well were seeded into 96-well plates containing 100 mL of
the growth medium in the absence or presence of increasing con-
centrations of nilotinib (0.1-100 nmol/L) and then incubated at
37C in 5%CO2 for 48 and 72 hours. After incubation period, the
cells were treated with 20 mLMTT for 4 hours. Then, plates were
centrifuged for 10minutes at 580g. After centrifugation, superna-
tants were removed from the plates, and then the MTT crystals
were homogenized by adding 100 mL DMSO into each well. In
order to homogenize the pellets more efficiently, the plates were
shaken for 5 minutes by shaker. Afterward, the plates were read
under 570 nm wavelengths by enzyme-linked immunosorbent
assay (ELISA) reader (Thermo Electron Corporation Multiskan
Spectrum, Finland). Finally, half maximal inhibitory concentra-
tion value (drug concentration that inhibits cell growth by 50%)
of nilotinib was calculated from the cell proliferation plots. The
effect of 48- and 72-hour nilotinib treatment on the confluency
of HCtAECs was also checked. To achieve this, HCtAECs were
seeded in 2 mL growth medium with a density of 1  106 cells/
well in 6-well plates. After attachment of the cells to the surface,
theywere treatedwith different concentrations of nilotinib (5, 50,
and 100 nmol/L).
Collection of HCtAECs Treated With Nilotinib for ELISA
Assay
The HCtAECs were seeded in 2 mL growth medium with a
density of 1  106 cells/well in 6-well plates. After attachment
of the cells to the surface, they were treated with different con-
centrations of nilotinib (5, 10, and 100 nmol/L) for 72 hours.
Control cultures were incubated with growth medium. After
72 hours incubation, cell culture supernatants were collected
and frozen at -80C before analysis by ELISA.
Determination of PAI-1, t-PA, ET-1, vWF, and Total NO
Levels by ELISA
The PAI-1 protein levels in supernatants were measured by
using sandwich ELISA kit (Wuhan Boster, Wuhan, China)
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which employs antihuman PAI-1 antibody as the capture anti-
body. Following kit instructions, the supernatant was incubated
in precoated microtest wells and was detected with a secondary
biotinylated antibody that recognizes the bound PAI-1 mole-
cules. Adding 100 mL avidin biotin peroxidase completed the
formation of the antibody–enzyme detection complex. After
the addition of 90 mL tetramethylbenzidine (TMB) substrate,
a blue-colored solution was formed. The levels of PAI-1 were
quantified by measuring solution absorbances at 450 nm and
comparing the values with those of a standard curve prepared
from 6 human PAI-1 standard dilutions.
Human t-PA platinum ELISA (e-Bioscience, California) kit
was used for quantitative detection of human t-PA in the super-
natants. This system includes microwells coated with antihu-
man t-PA coating antibody. The supernatant was added to
recoated microwells and then 50 mL horseradish peroxidase
(HRP)-conjugated antihuman t-PA antibody was added and
bound to human t-PA captured by the first antibody. Tetra-
methylbenzidine substrate of 100 mL was added, and colored
product was formed in proportion to the amount of human t-
PA present in the sample. Absorbance is measured at 450
nm. A standard curve is prepared from 7 human t-PA standard
dilutions and human t-PA concentration determined.
The ET-1 protein levels in supernatants were detected by
using human ET-1 sandwich ELISA kit (Cusabio, Wuhan,
China). Supernatants of 100 mL were pipetted into the wells
that were precoated with antihuman ET-1 antibody. Then,
100 mL biotin-conjugated antibody specific for ET-1 is added
to the wells. After washing, 100 mL avidin-conjugated HRP
was added to the wells. Following a wash to remove any
unbound avidin-enzyme reagent, 90 mL TMB solution was
added to the wells and color developed in proportion to the
amount of ET-1 bound in the initial step. The intensity of the
color was measured at 450 nm. A standard curve is prepared
from 6 human ET-1 standard dilutions.
To determine the vWF levels, sandwich ELISA kit (Assera-
chrom, Boehringer-Mannheim, Germany) using antihuman
vWF antibody as the capture antibody was used. Diluted super-
natants of 200 mL were put into the precoated microwells, and
then 200 mL anti-vWF peroxidase was added after several wash-
ing steps. Then, 200 mL TMB substrate was added to the wells,
and color intensity was measured at 450 nm. Levels of vWf were
determined by comparing the values with those of a standard
curve prepared from 4 human vWF standard dilutions.
For the quantitative determination of NO concentrations in
the supernatants, Total Nitric Oxide and Nitrate/Nitrite Assay
kit (R&D Systems, Minnesota) with 2 options, endogenous
nitrite and total nitrite measurements, was used. To obtain the
nitrite concentration, endogenous nitrite is subtracted from the
total nitrite value. Endogenous nitrite level was determined as a
first step. After the addition of 50 mL diluted samples to the
wells, 50 mL reaction diluent, 50 mL Griess reagent I (sulfani-
lamide), and 50 mL Griess reagent II (N-(1-naphthyl)ethylene-
diamine) were introduced into the wells in an order. The optical
density (OD) of each well was measured using a microplate
reader set at 540 nm, and endogenous nitrite concentration was
calculated by using a standard curve prepared from 6 nitrite
standards. As a second step, to measure the amount of total
nitrite, 50 mL diluted samples, 50 mL reaction diluent, 25 mL
b-nicotinamide adenine dinucleotide, and 25 mL nitrite reduc-
tase were added to the wells, and mixture is incubated at
37C. After incubation period, 50 mL Griess reagent I and 50
mL Griess reagent II were added and incubated at room tem-
perature. Finally, OD of each well was measured at 540 nm.
Total nitrite concentration was calculated by using a standard
curve prepared from 6 nitrite standards. The study was
approved by the local ethics committee of Dokuz Eylul
University.
Statistics
Results were expressed as mean + standard deviation. Data
were analyzed by 1-way analysis of variance followed by
Tukey post hoc test depending on the 6 measurements achieved
for each parameter. Values with P < .05 were accepted as sig-
nificant comparing control.
Results
Cytotoxic Effects of Nilotinib on HCtAECs
Cytotoxic effects of nilotinib on HCtAECs were determined by
MTT cell proliferation assay. Based on the MTT results, there
were very small but statistically significant decreases in the
proliferation of the cells in a dose- and time-dependent manner
(Figure 1). At higher concentrations of nilotinib (50 and
100 nmol/L), there were still approximately 80% alive cells
even after 72-hour treatment. Therefore, it could be concluded
that the treatment with nilotinib could not cause significant
damage to HCtAECs. The effect of nilotinib on the confluency
of HCtAECs was also visualized under microscope. Although
48-hour nilotinib treatment did not affect their confluency at
Figure 1. Cytotoxic effects of nilotinib on human carotid artery
endothelial cell (HCtAEC). The results are the means of 3 indepen-
dent experiments. The error bars represent the standard deviations.
Statistical significance was determined using 1-way analysis of variance,
and *P < .05 was considered to be significant.
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5 and 10 nmol/L nilotinib, there was 10% decrease in their con-
fluency at 100 nmol/L nilotinib applied samples as compared to
untreated control group. On the other hand, the cells were con-
fluent like control sample at 5 nmol/L nilotinib, but there were
10% and 20% decreases in their confluency at 10 and 100
nmol/L nilotinib after 72 hours incubation, respectively.
Effects of Nilotinib on the Secretory Functions
of HCtAECs
To determine the expressions of t-PA, PAI-1, ET-1, vWF, and
total NO in HCtAECs, we subjected the cells to increasing con-
centrations of nilotinib for 72 hours and assessed protein
Figure 2. Effects of nilotinib on the release of t-PA (A), plasminogen activator inhibitor 1 (PAI-1; B), endothelin 1 (ET-1; C), von Willebrand
factor (vWf; D), and nitric oxide (NO; E). The results are the means of 2 independent experiments. The error bars represent the standard
deviations. *P values <.05 were considered statistically significant.
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expression by ELISA. The investigation of the effect of
increasing concentrations of nilotinib on the secretion of t-PA
displayed that nilotinib caused 1.14-, 1.28-, and 1.32-fold
increases in t-PA levels from HCtAECs as compared to
untreated control cells in response to 5, 10, and 50 nmol/L nilo-
tinib, respectively (Figure 2A). On the other hand, there were
1.13-, 2.25-, and 2.5-fold increases in the expression of
PAI-1 at 72 hours (Figure 2B). As indicated in Figure 2C,
ET-1 expression was not significantly induced at 5 nmol/L
nilotinib but there were 1.14- and 1.35-fold increases at 10 and
100 nmol/L nilotinib, respectively. The expression of vWF
increased for 2.61- and 2.12-fold in response to 10 and 100
nmol/L nilotinib, respectively, although there was no signifi-
cant effect of 5 nmol/L nilotinib (Figure 2D). Moreover, total
nitride oxide level increased only at the highest nilotinib con-
centration when compared to untreated cells (Figure 2E).
Discussion
Incidence of CML and also the comorbid cardiovascular disor-
ders increase parallelly with aging. This issue has an important
impact on the therapeutic approaches, disease management,
prognosis, and even survival. Tyrosine kinase inhibitors revo-
lutionally altered the outcome of the disease. They are gener-
ally well tolerated and exhibits significantly less side effects
compared with the conventional chemotherapeutics. Neverthe-
less, especially in patients harboring cardiovascular risk fac-
tors, they can cause serious life-threatening side effects like
prolongation of QT time, symptomatic heart failure, and sud-
den cardiac death.12
Despite well-known and established cardiovascular side
effects, some rare toxicities and complications are being pub-
lished. Some of those important and life-threatening side
effects are therapy resistant or relapsing arterial occlusive and
coronary disorders, which are mainly affecting the patients on
nilotinib treatment or the ones which was switched to nilotinib.
In some cases, these unwanted occlusive events occur with no
attributable cardiovascular risk factor.6-8,13,14
At a recent work of Emir Hadzijusufovic et al, which was pre-
sented as a poster in ASH 2012 and not yet published, in vitro
effects of nilotinib on human umbilical vein endothelial cells
(HUVECs) were evaluated. They have shown that nilotinib, but
not imatinib, was found to inhibit HUVECmigration and sprout-
ing in a scratch-wound healing assay. Finally, nilotinib but not
imatinib was found to block the growth of various human pan-
creatic cell lines, including human caucasian pancreatic cell
line 1 (PANC-1) and the insulin-producing cell line 1.4E7. They
have concluded that their data showed that nilotinib exerts direct
inhibitory effects on endothelial cells and pancreatic cells. In
addition, the exact proatherogenic effect of nilotinib in second-
line- and first-line-treated patients with CML remains unknown
since nodata fromprospective clinical trials focusingon this issue
are available. Until these questions and safety issues have been
clarified, they mentioned that it may be advisable to take certain
comorbidities into account when considering the use of nilotinib
in patients with CML. In addition, the follow-up of long-term-
treated patients should include parameters that can detect vascu-
lar events and predisposing comorbidities as early as possible. In
this study of Hadzijusufovic, the examined cells were venous
cells, and the endothelial cell functions were not evaluated.
Considering the results obtained in our study, nilotinib does
not affect the functions of endothelial cells either in a pro-
thrombotic or an antithrombotic fashion. In this manner, speci-
fication of a tyrosine kinase pathway considering the
endothelial secretory functions affected with nilotinib is not
possible. The carotid artery endothelial cell viability decreases
with increasing doses of nilotinib. Thus, it can be suggested
that the ‘‘endothelial regeneration’’ under certain circum-
stances is impaired and can cause tendency to thrombosis in
patients using nilotinib. In addition to these implications, one
of the limitations of our study is the difficulty of constructing
net relevancy between the in vitro and in vivo conditions.
Besides, to our knowledge, this is the first report establishing
the effect of nilotinib on arterial endothelial cell viability and
function. Some further studies may better clarify the mechan-
ism responsible from the cytotoxic effect of nilotinib on
endothelial cells and contribute to a better knowledge to man-
age these unwanted life-threatening occlusive side effects.
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